𝗧𝗵𝗲 𝗚𝗮𝗺𝗲𝘁𝗼 𝗚𝗮𝗺𝗯𝗶𝘁 — We’re proud to kick off the […]

𝗧𝗵𝗲 𝗚𝗮𝗺𝗲𝘁𝗼 𝗚𝗮𝗺𝗯𝗶𝘁 — We’re proud to kick off the new year with the Series A for Gameto, to support their vision to improve assisted fertility and prolong reproductive longevity by forestalling ovarian aging and menopause.

TechCrunch today: “Gameto just raised $20 million in funding led by Future Ventures, whose cofounder, Maryanna Saenko, says the firm is ‘deeply excited about the prospect of a better standard of care for women undergoing menopause. The suffering caused by menopause is not a biological imperative, and the many complications that come along with menopause, particularly early-onset menopause, can be entirely avoided’”

PR Newswire: “With some of the initial research conducted at the George Church lab at Harvard Medical School, Gameto has achieved ground-breaking results in creating the first human reprogrammed cells of the ovary (granulosa cells & oocytes precursors) to solve the problem of accelerated ovarian aging, which occurs up to five times faster than any organ in the body.

Gameto is building a platform for ovarian therapeutics to initially improve assisted fertility and address menopause with three sequenced programs:
1) Fertilo – To improve assisted fertility and with the mission to eliminate infertility over time for all women.
2) Deovo – To initiate drug discovery and a computational platform for ovarian aging.
3) Ameno – Aiming to make the medical burden of menopause optional.

Based on the rapid aging nature of ovaries, they are an excellent model to study human aging. Gameto wants to synchronize the pace of ovarian aging to the rate of aging in other organs such as the liver, brain, or skin. When ovaries are termed “geriatric” by many traditional medical criteria, the rest of the body is certainly not and this has contributed to the societal and demographic issues we are facing today. Considering human healthspan and lifespan have increased significantly, Gameto believes this biological phenomenon is no longer fit for purpose and is a problem worth solving. Gameto sees the potential to expand its platform to the entire aging market.

‘Ovaries age five times faster than other organs, resulting in infertility, early menopause and increased years of poor health for women. We want to change the narrative of female reproductive longevity and address the root causes of sex/gender inequality in our society.’ said Dr. Dina Radenkovic, CEO of Gameto.”

— Deep dive: https://www.longevity.technology/gameto-23m-gamechanger-for-female-reproductive-fertility-is-born/
— TechCrunch: https://techcrunch.com/2022/01/10/with-funding-from-top-investors-gameto-is-aiming-to-delay-even-eradicate-menopause/
— PR Newswire: https://www.prnewswire.com/news-releases/gameto-raises-23m-to-redefine-reproductive-longevity-with-reprogrammed-ovarian-cells-301456850.html
— Company: https://gametogen.com